Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
about
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumorsEstablishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression dataRSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.Cyclin D as a therapeutic target in cancerPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsFrequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models.Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaMolecular characterisation of cell line models for triple-negative breast cancers.Molecular Heterogeneity of Triple Negative Breast Cancer.Subtyping of triple-negative breast cancer: implications for therapyCross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.TMEM16A overexpression contributes to tumor invasion and poor prognosis of human gastric cancer through TGF-β signaling.FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinomaMYC amplification in breast cancer: a chromogenic in situ hybridisation studyDual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease.Clinical Implications of FADD Gene Amplification and Protein Overexpression in Taiwanese Oral Cavity Squamous Cell Carcinomas.Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpartExpression of Cyclin D1 Is Associated with β-Catenin Expression and Correlates with Good Prognosis in Colorectal Adenocarcinoma.Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase.Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma.The cyclin D1b splice variant: an old oncogene learns new tricks.Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumorsSilencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis.Immunophenotypic and genomic characterization of papillary carcinomas of the breast.Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation.Role of cyclin D1 in breast carcinomaPIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.DNA amplifications in breast cancer: genotypic-phenotypic correlations.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
P2860
Q21183964-EBF2D24B-AAE5-4674-9674-8E0F36F83076Q24684071-42B7F5E8-7044-4E3C-B5DA-C0A34F74A623Q27852757-1C3E1CC8-49CE-4F24-AAF9-0A04EBA85C55Q28242623-FA51B2C4-291D-47B8-9B38-284F24FD04D3Q28265304-4D768618-D6CA-4294-B878-EA0DF902E8E3Q33260375-6676498A-1C14-4FA9-B14F-71ADBD91EFBFQ33428469-D0B572D5-8F08-4AE0-AA82-731D6E2CBE5EQ33677510-F0D11AC2-7913-4D09-AE06-D1F3245AB31AQ33867326-5DA1DBE1-E1D5-443A-BFE6-0A7580EAE1C7Q34064466-B3B9C2C7-D8FA-4C71-90C3-E387082B3AC6Q34476551-67BD0894-3C30-471A-9E7D-4D443D25DC06Q34533964-C8A15500-5E81-4DD2-9848-9761B426A2CAQ34734477-C0A8F485-9482-4049-A7B9-FE9E665E379EQ35127769-E3222A48-2FD3-4830-8585-315D465A7AABQ35793867-06DECDE1-8998-4F51-A70F-9052597EAADEQ35794378-CE2AA6C3-1842-40DB-8D09-99175766D5E8Q35854244-CE52DA67-560A-42B0-9DE7-EA40D761C1F2Q35984487-DE2DCA55-62E8-432A-90A7-5D5493BBA6F3Q36002746-BBC08E61-0A82-4AF4-9E74-FA994368CE99Q36169254-1A7F4C49-C7C6-49A2-BCD6-655E90CA9876Q36244809-D7A03E27-0B6D-4652-8284-26FAF8593B30Q36310657-6055F461-B2F8-4C90-9BF2-6DDA90C75724Q36464413-BE0FBEE5-8779-4B34-82EC-B4837AA92C8BQ36473652-FF85A993-20D8-446D-8A76-40E8ED4E8584Q36545151-A59F0408-E1F0-4867-AB5C-B234C2950C7CQ36595121-985565E8-1A3A-4990-9EC8-8D61B02AAC9BQ36707456-62860183-0307-4382-891E-13AC9F8C2765Q37071327-C17C19DC-A485-4532-933F-F83F4F45C130Q37130628-55D37E0B-9018-43C3-8D4F-C00DF27EEECCQ37304652-F504BC93-5389-4895-8A22-DD0D9BEAE0CEQ37360938-181E6CB6-E1A3-4C3B-8CA6-FA732CEE7460Q37536936-4995A240-DEB3-49CA-8159-D703B581CBBFQ37589094-074E83E9-B05C-4C24-A88C-5B22EF0BE2FCQ37678826-82E797D1-15E3-4AFB-BDF2-B029F4C182B8Q37763102-E6690A49-857C-4EA2-8D0A-83E6308D4FABQ37809456-025C3A1E-97D5-4822-9656-1B9751C73B93Q37843728-ECAF6CE8-6D96-4468-BB27-B66FFF6197BDQ37948079-00B5FBAA-7220-46AE-9FAA-E1A810A07178Q38066149-BDA9ECEF-5441-43C2-BC45-81921602946CQ38675849-0DEBC2A2-4ED9-45E5-B068-245904AD99AA
P2860
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@en
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@nl
type
label
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@en
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@nl
prefLabel
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@en
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@nl
P2093
P2860
P1433
P1476
Cyclin D1 protein overexpressi ...... n situ hybridisation analysis.
@en
P2093
Dawn Steele
Kay Savage
Maryou B K Lambros
Michelle James
Robin L Jones
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800621
P577
2006-04-28T00:00:00Z
P5875
P6179
1048206794